Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genscript Biotech ( (HK:1548) ) just unveiled an announcement.
Genscript Biotech Corporation announced that its associate, Legend Biotech Corporation, will present new data on CARVYKTI® and other pipeline products at the upcoming American Society of Hematology Annual Meeting. This announcement highlights Legend’s ongoing efforts in the field of hematology and could potentially enhance its industry positioning by showcasing advancements in their product offerings.
The most recent analyst rating on (HK:1548) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.
More about Genscript Biotech
Genscript Biotech Corporation is a company incorporated in the Cayman Islands, focusing on biotechnology. Its primary products and services include advancements in biopharmaceuticals, with a market focus on innovative therapies and treatments.
YTD Price Performance: 63.62%
Average Trading Volume: 15,062,626
Technical Sentiment Signal: Buy
Current Market Cap: HK$35B
See more data about 1548 stock on TipRanks’ Stock Analysis page.